The EGFR and EGFR ligand reference intervals established in a previous study33 enables evaluation of levels of EGFR and EGFR ligands in breast cancer patients against reference intervals and not only by groups comparison, as done in previous studies. The gene discussed is EGFR; the disease is breast carcinoma.